245 related articles for article (PubMed ID: 34113011)
1. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Lakeman IMM; van den Broek AJ; Vos JAM; Barnes DR; Adlard J; Andrulis IL; Arason A; Arnold N; Arun BK; Balmaña J; Barrowdale D; Benitez J; Borg A; Caldés T; Caligo MA; Chung WK; Claes KBM; ; ; Collée JM; Couch FJ; Daly MB; Dennis J; Dhawan M; Domchek SM; Eeles R; Engel C; Evans DG; Feliubadaló L; Foretova L; Friedman E; Frost D; Ganz PA; Garber J; Gayther SA; Gerdes AM; Godwin AK; Goldgar DE; Hahnen E; Hake CR; Hamann U; Hogervorst FBL; Hooning MJ; Hopper JL; Hulick PJ; Imyanitov EN; ; ; ; Isaacs C; Izatt L; Jakubowska A; James PA; Janavicius R; Jensen UB; Jiao Y; John EM; Joseph V; Karlan BY; Kets CM; Konstantopoulou I; Kwong A; Legrand C; Leslie G; Lesueur F; Loud JT; Lubiński J; Manoukian S; McGuffog L; Miller A; Gomes DM; Montagna M; Mouret-Fourme E; Nathanson KL; Neuhausen SL; Nevanlinna H; Yie JNY; Olah E; Olopade OI; Park SK; Parsons MT; Peterlongo P; Piedmonte M; Radice P; Rantala J; Rennert G; Risch HA; Schmutzler RK; Sharma P; Simard J; Singer CF; Stadler Z; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teo SH; Teulé A; Thomassen M; Thull DL; Tischkowitz M; Toland AE; Tung N; van Rensburg EJ; Vega A; Wappenschmidt B; Devilee P; van Asperen CJ; Bernstein JL; Offit K; Easton DF; Rookus MA; Chenevix-Trench G; Antoniou AC; Robson M; Schmidt MK
Genet Med; 2021 Sep; 23(9):1726-1737. PubMed ID: 34113011
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.
Kramer I; Hooning MJ; Mavaddat N; Hauptmann M; Keeman R; Steyerberg EW; Giardiello D; Antoniou AC; Pharoah PDP; Canisius S; Abu-Ful Z; Andrulis IL; Anton-Culver H; Aronson KJ; Augustinsson A; Becher H; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bogdanova NV; Bojesen SE; Bolla MK; Bonanni B; Brauch H; Bremer M; Brucker SY; Burwinkel B; Castelao JE; Chan TL; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Choi JY; Clarke CL; ; Collée JM; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; Dos-Santos-Silva I; Dunning AM; Dwek M; Eccles DM; Evans DG; Fasching PA; Flyger H; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Giles GG; Goldgar DE; González-Neira A; Haiman CA; Håkansson N; Hamann U; Hartman M; Heemskerk-Gerritsen BAM; Hollestelle A; Hopper JL; Hou MF; Howell A; ; ; Ito H; Jakimovska M; Jakubowska A; Janni W; John EM; Jung A; Kang D; Kets CM; Khusnutdinova E; Ko YD; Kristensen VN; Kurian AW; Kwong A; Lambrechts D; Le Marchand L; Li J; Lindblom A; Lubiński J; Mannermaa A; Manoochehri M; Margolin S; Matsuo K; Mavroudis D; Meindl A; Milne RL; Mulligan AM; Muranen TA; Neuhausen SL; Nevanlinna H; Newman WG; Olshan AF; Olson JE; Olsson H; Park-Simon TW; Peto J; Petridis C; Plaseska-Karanfilska D; Presneau N; Pylkäs K; Radice P; Rennert G; Romero A; Roylance R; Saloustros E; Sawyer EJ; Schmutzler RK; Schwentner L; Scott C; See MH; Shah M; Shen CY; Shu XO; Siesling S; Slager S; Sohn C; Southey MC; Spinelli JJ; Stone J; Tapper WJ; Tengström M; Teo SH; Terry MB; Tollenaar RAEM; Tomlinson I; Troester MA; Vachon CM; van Ongeval C; van Veen EM; Winqvist R; Wolk A; Zheng W; Ziogas A; Easton DF; Hall P; Schmidt MK
Am J Hum Genet; 2020 Nov; 107(5):837-848. PubMed ID: 33022221
[TBL] [Abstract][Full Text] [Related]
3. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
Barnes DR; Silvestri V; Leslie G; McGuffog L; Dennis J; Yang X; Adlard J; Agnarsson BA; Ahmed M; Aittomäki K; Andrulis IL; Arason A; Arnold N; Auber B; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Barwell J; Belotti M; Benitez J; Berthet P; Boonen SE; Borg Å; Bozsik A; Brady AF; Brennan P; Brewer C; Brunet J; Bucalo A; Buys SS; Caldés T; Caligo MA; Campbell I; Cassingham H; Christensen LL; Cini G; Claes KBM; ; ; Cook J; Coppa A; Cortesi L; Damante G; Darder E; Davidson R; de la Hoya M; De Leeneer K; de Putter R; Del Valle J; Diez O; Ding YC; Domchek SM; Donaldson A; Eason J; Eeles R; Engel C; Evans DG; Feliubadaló L; Fostira F; Frone M; Frost D; Gallagher D; Gehrig A; Giraud S; Glendon G; Godwin AK; Goldgar DE; Greene MH; Gregory H; Gross E; Hahnen E; Hamann U; Hansen TVO; Hanson H; Hentschel J; Horvath J; ; ; Izatt L; Izquierdo A; James PA; Janavicius R; Jensen UB; Johannsson OT; John EM; Kramer G; Kroeldrup L; Kruse TA; Lautrup C; Lazaro C; Lesueur F; Lopez-Fernández A; Mai PL; Manoukian S; Matrai Z; Matricardi L; Maxwell KN; Mebirouk N; Meindl A; Montagna M; Monteiro AN; Morrison PJ; Muranen TA; Murray A; Nathanson KL; Neuhausen SL; Nevanlinna H; Nguyen-Dumont T; Niederacher D; Olah E; Olopade OI; Palli D; Parsons MT; Pedersen IS; Peissel B; Perez-Segura P; Peterlongo P; Petersen AH; Pinto P; Porteous ME; Pottinger C; Pujana MA; Radice P; Ramser J; Rantala J; Robson M; Rogers MT; Rønlund K; Rump A; Sánchez de Abajo AM; Shah PD; Sharif S; Side LE; Singer CF; Stadler Z; Steele L; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teulé A; Thull DL; Tischkowitz M; Toland AE; Tommasi S; Toss A; Trainer AH; Tripathi V; Valentini V; van Asperen CJ; Venturelli M; Viel A; Vijai J; Walker L; Wang-Gohrke S; Wappenschmidt B; Whaite A; Zanna I; Offit K; Thomassen M; Couch FJ; Schmutzler RK; Simard J; Easton DF; Chenevix-Trench G; Antoniou AC; Ottini L;
J Natl Cancer Inst; 2022 Jan; 114(1):109-122. PubMed ID: 34320204
[TBL] [Abstract][Full Text] [Related]
4. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
Barnes DR; Rookus MA; McGuffog L; Leslie G; Mooij TM; Dennis J; Mavaddat N; Adlard J; Ahmed M; Aittomäki K; Andrieu N; Andrulis IL; Arnold N; Arun BK; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Benitez J; Berthet P; Białkowska K; Blanco AM; Blok MJ; Bonanni B; Boonen SE; Borg Å; Bozsik A; Bradbury AR; Brennan P; Brewer C; Brunet J; Buys SS; Caldés T; Caligo MA; Campbell I; Christensen LL; Chung WK; Claes KBM; Colas C; ; ; Collonge-Rame MA; Cook J; Daly MB; Davidson R; de la Hoya M; de Putter R; Delnatte C; Devilee P; Diez O; Ding YC; Domchek SM; Dorfling CM; Dumont M; Eeles R; Ejlertsen B; Engel C; Evans DG; Faivre L; Foretova L; Fostira F; Friedlander M; Friedman E; Frost D; Ganz PA; Garber J; Gehrig A; Gerdes AM; Gesta P; Giraud S; Glendon G; Godwin AK; Goldgar DE; González-Neira A; Greene MH; Gschwantler-Kaulich D; Hahnen E; Hamann U; Hanson H; Hentschel J; Hogervorst FBL; Hooning MJ; Horvath J; Hu C; Hulick PJ; Imyanitov EN; ; ; ; Isaacs C; Izatt L; Izquierdo A; Jakubowska A; James PA; Janavicius R; John EM; Joseph V; Karlan BY; Kast K; Koudijs M; Kruse TA; Kwong A; Laitman Y; Lasset C; Lazaro C; Lester J; Lesueur F; Liljegren A; Loud JT; Lubiński J; Mai PL; Manoukian S; Mari V; Mebirouk N; Meijers-Heijboer HEJ; Meindl A; Mensenkamp AR; Miller A; Montagna M; Mouret-Fourme E; Mukherjee S; Mulligan AM; Nathanson KL; Neuhausen SL; Nevanlinna H; Niederacher D; Nielsen FC; Nikitina-Zake L; Noguès C; Olah E; Olopade OI; Ong KR; O'Shaughnessy-Kirwan A; Osorio A; Ott CE; Papi L; Park SK; Parsons MT; Pedersen IS; Peissel B; Peixoto A; Peterlongo P; Pfeiler G; Phillips KA; Prajzendanc K; Pujana MA; Radice P; Ramser J; Ramus SJ; Rantala J; Rennert G; Risch HA; Robson M; Rønlund K; Salani R; Schuster H; Senter L; Shah PD; Sharma P; Side LE; Singer CF; Slavin TP; Soucy P; Southey MC; Spurdle AB; Steinemann D; Steinsnyder Z; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teo SH; Thull DL; Tischkowitz M; Tognazzo S; Toland AE; Trainer AH; Tung N; van Engelen K; van Rensburg EJ; Vega A; Vierstraete J; Wagner G; Walker L; Wang-Gohrke S; Wappenschmidt B; Weitzel JN; Yadav S; Yang X; Yannoukakos D; Zimbalatti D; Offit K; Thomassen M; Couch FJ; Schmutzler RK; Simard J; Easton DF; Chenevix-Trench G; Antoniou AC;
Genet Med; 2020 Oct; 22(10):1653-1666. PubMed ID: 32665703
[TBL] [Abstract][Full Text] [Related]
5. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
[TBL] [Abstract][Full Text] [Related]
6. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
7. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
8. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
Akdeniz D; van Barele M; Heemskerk-Gerritsen BAM; Steyerberg EW; Hauptmann M; ; van de Beek I; van Engelen K; Wevers MR; Gómez García EB; Ausems MGEM; Berger LPV; van Asperen CJ; Adank MA; Collée MJ; Stommel-Jenner DJ; Jager A; Schmidt MK; Hooning MJ
Breast; 2022 Feb; 61():98-107. PubMed ID: 34929424
[TBL] [Abstract][Full Text] [Related]
9. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
10. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; John EM; Brooks JD; Lynch CF; Bernstein L; Mellemkjær L; Malone KE; Knight JA; Capanu M; Teraoka SN; Concannon P; Liang X; Figueiredo JC; Smith SA; Stovall M; Pike MC; Haile RW; Thomas DC; Begg CB; Bernstein JL
J Clin Oncol; 2013 Feb; 31(4):433-9. PubMed ID: 23269995
[TBL] [Abstract][Full Text] [Related]
11. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; McGuffog L; Barrowdale D; Lee A; Soucy P; Dennis J; Domchek SM; Robson M; Spurdle AB; Ramus SJ; Mavaddat N; Terry MB; Neuhausen SL; Schmutzler RK; Simard J; Pharoah PDP; Offit K; Couch FJ; Chenevix-Trench G; Easton DF; Antoniou AC
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376175
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
14. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
16. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
[TBL] [Abstract][Full Text] [Related]
17. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Mavaddat N; Peock S; Frost D; Ellis S; Platte R; Fineberg E; Evans DG; Izatt L; Eeles RA; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Tischkowitz M; Douglas F; Hodgson S; Walker L; Porteous ME; Morrison PJ; Side LE; Kennedy MJ; Houghton C; Donaldson A; Rogers MT; Dorkins H; Miedzybrodzka Z; Gregory H; Eason J; Barwell J; McCann E; Murray A; Antoniou AC; Easton DF;
J Natl Cancer Inst; 2013 Jun; 105(11):812-22. PubMed ID: 23628597
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
19. The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
Laitman Y; Kuchenbaecker KB; Rantala J; Hogervorst F; Peock S; Godwin AK; Arason A; Kirchhoff T; Offit K; Isaacs C; Schmutzler RK; Wappenschmidt B; Nevanlinna H; Chen X; Chenevix-Trench G; Healey S; Couch F; Peterlongo P; Radice P; Nathanson KL; Caligo MA; Neuhausen SL; Ganz P; Sinilnikova OM; McGuffog L; Easton DF; Antoniou AC; Wolf I; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(3):1119-26. PubMed ID: 22212556
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
